Management of dyslipidaemias

Heart

Volumn 92, Issue 10, 2006, Pages 1529-1534

  Paramsothy, Pathmaja ^a,b   Knopp, Robert ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

^b UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMIODARONE; ANTIFUNGAL AGENT; APOLIPOPROTEIN B; ATORVASTATIN; BILE ACID SEQUESTRANT; CHOLESTEROL; COLESTIPOL; COLESTYRAMINE; COLSEVELAM; CREATINE KINASE; CYCLOSPORIN; EZETIMIBE; FIBRIC ACID DERIVATIVE; GEMFIBROZIL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN; MACROLIDE; MEVINOLIN; NEFAZODONE; NICOTINIC ACID; PRAVASTATIN; PROTEINASE INHIBITOR; PYRROLE DERIVATIVE; ROSUVASTATIN; SIMVASTATIN; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; UNINDEXED DRUG; VERAPAMIL; WARFARIN;

CARDIOVASCULAR DISEASE; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONCENTRATION LOSS; CONSTIPATION; CREATINE KINASE BLOOD LEVEL; DIET THERAPY; DRUG USE; DYSLIPIDEMIA; DYSPNEA; FLATULENCE; HUMAN; HYPERCHLOREMIC ACIDOSIS; INSOMNIA; ISCHEMIC HEART DISEASE; LIPOPROTEIN BLOOD LEVEL; LIVER DYSFUNCTION; LIVER FAILURE; MYOSITIS; PERIPHERAL NEUROPATHY; PRACTICE GUIDELINE; PRIORITY JOURNAL; RASH; REVIEW; RHABDOMYOLYSIS; RISK ASSESSMENT; SCORING SYSTEM; TRIACYLGLYCEROL BLOOD LEVEL;

ANTICHOLESTEREMIC AGENTS; ANTILIPEMIC AGENTS; DIET; DYSLIPIDEMIAS; HUMANS; TRIGLYCERIDES;

EID: 33750072325     PISSN: 13556037     EISSN: None     Source Type: Journal    
DOI: 10.1136/hrt.2005.071712     Document Type: Review

References (25)

1. Yusuf S, Reddy S, Ounpuu S, et al. Global burden of cardiovascular diseases: part I: general considerations, the epidemiologic transition, risk factors, and impact of urbanization. Circulation 2001;104:2746-53.
2. Yusuf S, Reddy S, Ounpuu S, et al. Global burden of cardiovascular diseases: part II: variations in cardiovascular disease by specific ethnic groups and geographic regions and prevention strategies. Circulation 2001;104:2855-64.
3. Yusuf S, Hawken S, Ounpuu S, et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet 2004;364:937-52. This landmark study demonstrates that traditional risk factors for CHD account for > 90% of the CHD risk worldwide. It evaluates risk in a wide spectrum of peoples.
4. De Backer G, Ambrosioni E, Borch-Johnsen K, et al. European guidelines on cardiovascular disease prevention in clinical practice. Third Joint Task Force of European and Other Societies on Cardiovascular Disease Prevention in Clinical Practice. Eur Heart J 2003;24:1601-10, These guidelines are a consensus statement which discusses the important elements of CHD prevention in Europeans.
5. National Cholesterol Education Program. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002;106:3143-421. These guidelines are a consensus statement which discusses the diagnosis and treatment of high cholesterol in terms of CHD prevention in Americans.
6. Grundy SM, Cleeman JI, Merz CN, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines. J Am Coll Cardiol 2004;44:720-32. This important update to the NCEP/ATP III guidelines reviews recent trials and documents the benefits of additional LDL lowering in high risk and very high risk groups for cardiovascular disease.
7. Knopp RH. Drug treatment of lipid disorders. N Engl J Med 1999;341:498-511. This review discusses the pathophysiology of common lipid disorders and the role of various drug treatments.
8. Conroy RM, Pyorala K, Fitzgerald AP, et al. Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project. Eur Heart J 2003;24:987-1003.
9. Cannon CP, Braunwald E, McCabe CH, et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 2004;350:1495-504.
10. Grundy SM, Cleeman JI, Daniels SR, et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation 2005;112:2735-52. This recent review discusses the most recent definition of metabolic syndrome and the important aspects of management of this disorder which is highly prevalent.
11. Ridker PM, Cannon CP, Morrow D, et al. C-reactive protein levels and outcomes after statin therapy. N Engl J Med 2005;352:20-8.
12. Pasternak RC, Smith SC Jr, Bairey-Merz CN, et al. ACC/AHA/NHLBI clinical advisory on the use and safety of statins. J Am Coll Cardiol 2002;40:567-72. This article directs the practitioner in the monitoring of statins, including how to monitor and when to change or discontinue treatment.
13. Mauro VF, Tuckerman CE. Ezetimibe for management of hypercholesterolemia. Ann Pharmacother 2003;37:839-48.
14. Jeppesen J, Hein HO, Suadicani P, et al. Triglyceride concentration and ischemic heart disease: an eight-year follow-up in the Copenhagen Male Study. Circulation 1998;97:1029-36.
15. Rubins HB, Robins SJ, Collins D, et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. N Engl J Med 1999;341:410-18.
16. Tanne D, Koren-Morag N, Graff E, et al. Blood lipids and first-ever ischemic stroke/transient ischemic attack in the Bezafibrate Infarction Prevention (BIP) Registry: high triglycerides constitute an independent risk factor. Circulation 2001;104:2892-7.
17. Keech A, Simes RJ, Barter P, et al. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet 2005;366:1849-61.
18. Maki KC, Van Elswyk ME, McCarthy D, et al. Lipid responses to a dietary docosahexaenoic acid supplement in men and women with below average levels of high density lipoprotein cholesterol. J Am Coll Nutr 2005;24:189-99.
19. Kris-Etherton PM, Harris WS, Appel LJ. Omega-3 fatty acids and cardiovascular disease: new recommendations from the American Heart Association. Arterioscler Thromb Vasc Biol 2003;23:151-2.
20. Ashen MD, Blumenthal RS. Clinical practice. Low HDL cholesterol levels. N Engl J Med 2005;353:1252-60. This article reviews the treatment of low HDL cholesterol and how to improve low HDL cholesterol by behavioural changes as well as with drug treatment.
21. Canner PL, Berge KG, Wenger NK, et al. Fifteen year mortality in Coronary Drug Project patients: long-term benefit with niacin. J Am Coll Cardiol 1986;8:1245-55.
22. Forrester JS, Makkar R, Shah PK. Increasing high-density lipoprotein cholesterol in dyslipidemia by cholesteryl ester transfer protein inhibition: an update for clinicians. Circulation 2005;111:1847-54. This recent review discusses the role of CETP inhibitors in the treatment of low HDL from a mechanistic perspective.
23. Knopp RH, Retzlaff B, Fish B, et al. Effects of insulin resistance and obesity on lipoproteins and sensitivity to egg feeding. Arterioscler Thromb Vasc Biol 2003;23:1437-43.
24. Dansinger ML, Gleason JA, Griffith JL, et al. Comparison of the Atkins, Ornish, Weight Watchers, and Zone diets for weight loss and heart disease risk reduction: a randomized trial. JAMA 2005;293:43-53.
25. Chobanian AV, Bakins GL, Black HR, et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure: the JNC 7 report. JAMA 2003;289:2560-72.